^
Association details:
| Biomarker: | U2AF1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Excerpt:
...CSF3R (exons 14, 15, 17), EZH2 (exons 15-20), FBXW7 (CDS), FGFR1 (exons 4, 11-17, partial 18), FLT3 (p.D835H), GATA1 (exons 2-3), GATA2 (exons 3-5), HRAS (exon 1-2), IDH1(p.R132), IDH2 (exon 4), JAK2 (exon 12, 14, 16), KIT (8-18), KMT2A (CDS), KRAS (CDS), MAP2K1 (exons 2, 3, 6), MPL (exon 10), MYD88 (exon 3-5), NOTCH1 (exons 20, 26, 27), NPM1 (exon 12), NRAS (CDS), PDGFRA (exons 12-18), PHF6 (CDS), PTEN (CDS), RB1 (CDS), RUNX1 (exon 4-8), SF3B1 (exon 14-16), SRSF2 (exon 1), STAG2 (CDS), STAT3 (exons 20-21), TP53 (CDS), U2AF1 (exons 2, 6), WT1 (CDS), and ZRSR2 (CDS) -...
Trial ID:
Source:
Title:
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
Excerpt:
...- U2AF1...
Trial ID:
Less C2 evidence
Source:
Title:
1911 Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy
Published date:
11/04/2020
Excerpt:
We identified 290 consecutive adult patients treated with standard induction chemotherapy (“7+3” with cytarabine and an anthracycline, or CPX-351) for newly diagnosed AML...the presence of TP53 mutation, U2AF1 mutation, or 11q23 rearrangement were independently associated with inferior OS after day 60, whereas the presence of CBF rearrangement was independently associated with superior OS after day 60...
Secondary therapy:
cytarabine
